NO176799C - DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid - Google Patents

DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid

Info

Publication number
NO176799C
NO176799C NO875378A NO875378A NO176799C NO 176799 C NO176799 C NO 176799C NO 875378 A NO875378 A NO 875378A NO 875378 A NO875378 A NO 875378A NO 176799 C NO176799 C NO 176799C
Authority
NO
Norway
Prior art keywords
polypeptide
encodes
express
producing
dna encoding
Prior art date
Application number
NO875378A
Other languages
English (en)
Norwegian (no)
Other versions
NO176799B (no
NO875378D0 (no
NO875378L (no
Inventor
Tetsuro Kuga
Yoshinori Komatsu
Hiromasa Miyaji
Moriyuki Sato
Masami Okabe
Makoto Morimoto
Seiga Itoh
Motoo Yamasaki
Yoshiharu Yokoo
Kazuo Yamaguchi
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17961392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO176799(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO875378D0 publication Critical patent/NO875378D0/no
Publication of NO875378L publication Critical patent/NO875378L/no
Priority to NO19940495A priority Critical patent/NO315003B1/no
Publication of NO176799B publication Critical patent/NO176799B/no
Publication of NO176799C publication Critical patent/NO176799C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO875378A 1986-12-23 1987-12-22 DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid NO176799C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO19940495A NO315003B1 (no) 1986-12-23 1994-02-14 Fremgangsmåte for fremstilling av polypeptid samt DNA-sekvens som koder fordette

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30679986 1986-12-23

Publications (4)

Publication Number Publication Date
NO875378D0 NO875378D0 (no) 1987-12-22
NO875378L NO875378L (no) 1988-06-24
NO176799B NO176799B (no) 1995-02-20
NO176799C true NO176799C (no) 1995-05-31

Family

ID=17961392

Family Applications (1)

Application Number Title Priority Date Filing Date
NO875378A NO176799C (no) 1986-12-23 1987-12-22 DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid

Country Status (10)

Country Link
EP (1) EP0272703B2 (es)
JP (1) JPH068317B2 (es)
KR (1) KR960016560B1 (es)
CA (1) CA1341522C (es)
DE (1) DE3786767T3 (es)
DK (1) DK174044B1 (es)
ES (1) ES2059354T5 (es)
HK (1) HK164195A (es)
NO (1) NO176799C (es)
PT (1) PT86465B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US7119182B1 (en) 1991-02-19 2006-10-10 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US6245900B1 (en) 1994-02-23 2001-06-12 Kyowa Hakko Kogyo Co., Ltd. Platelet production promoting agent
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6100070A (en) * 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
DE19860801A1 (de) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Rekombinanter Wachstumsfaktor mit der biologischen Aktivität eines G-CSF (Granulocyte Colony Stimulating Factor)
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
CA2421760A1 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
ATE399794T1 (de) * 2001-02-06 2008-07-15 Merck Patent Gmbh Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
KR100508358B1 (ko) 2002-03-20 2005-08-17 주식회사 바이오폴리메드 생체적합성 고분자가 시스테인 잔기에 화학양론적으로 결합된 ｇ-ｃｓｆ의 제조 방법
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2004075913A1 (ja) 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP1817047B1 (en) 2004-11-05 2012-02-08 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
CN101193658B (zh) 2005-06-01 2011-08-31 马克西根控股公司 聚乙二醇化g-csf多肽及其产生方法
EP2094274A4 (en) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR BONE MARROW RECOVERY
EP2185689A2 (en) 2007-08-09 2010-05-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
JP5715622B2 (ja) 2009-06-14 2015-05-07 バイオカイン セラピューティックス リミテッド 血小板レベルを増大させるためのペプチド療法
CN107412737A (zh) 2010-01-19 2017-12-01 韩美科学株式会社 长效g‑csf缀合物的液体制剂
ES2639398T3 (es) 2010-03-04 2017-10-26 Pfenex Inc. Método para producir proteína de interferón recombinante soluble sin desnaturalización
US8455218B2 (en) 2010-04-01 2013-06-04 Pfenex, Inc. Methods for G-CSF production in a Pseudomonas host cell
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4869987A (es) 1971-12-27 1973-09-22
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
EP0215126B1 (en) * 1985-02-08 1991-07-31 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
ATE67517T1 (de) * 1985-09-30 1991-10-15 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH01500483A (ja) 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
JP2581110B2 (ja) * 1987-10-26 1997-02-12 いすゞ自動車株式会社 パティキュレートトラップの再燃焼装置

Also Published As

Publication number Publication date
DK680987A (da) 1988-06-24
KR960016560B1 (ko) 1996-12-14
ES2059354T3 (es) 1994-11-16
NO176799B (no) 1995-02-20
PT86465A (en) 1988-01-01
DE3786767D1 (de) 1993-09-02
JPH068317B2 (ja) 1994-02-02
HK164195A (en) 1995-10-27
NO875378D0 (no) 1987-12-22
DE3786767T3 (de) 1998-04-16
KR880007734A (ko) 1988-08-29
EP0272703A1 (en) 1988-06-29
JPS63267292A (ja) 1988-11-04
DK680987D0 (da) 1987-12-22
ES2059354T5 (es) 1998-03-16
DK174044B1 (da) 2002-05-06
EP0272703B1 (en) 1993-07-28
CA1341522C (en) 2007-03-13
NO875378L (no) 1988-06-24
PT86465B (pt) 1990-11-20
DE3786767T2 (de) 1994-01-13
EP0272703B2 (en) 1997-10-15

Similar Documents

Publication Publication Date Title
NO176799C (no) DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
ZA822855B (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
DK597288D0 (da) Rekombinant, humant immunoglobulin og fremgangsmaade til fremstilling deraf
KR880701557A (ko) 변형인자 ⅷ:c 및 변형인자ⅷ:c-유사 폴리펠티드를 코오딩하는 dna서열 및 이들 폴리펩티드를 고수율로 제조하는 방법
ES8802159A1 (es) Un procedimiento de producir un acido desoxirribonucleico (adn)que tiene o contiene una secuencia de base que codificaun polipeptido de factor de necrosis tumoral de humano
DK0962531T3 (da) Interferon-gammaproduktion inducerende isoleret polypeptidfragment og et isolaret DNA-fragment der koder for dette polypeptid
NO882385D0 (no) Polypeptid og produksjon derav.
IL70856A0 (en) Dna sequences,recombinant dna molecules and processes for producing human interleukin two-like polypeptides
NO845132L (no) Humant interferon-ypsilon-polypeptidderivat, fremgangsmaate for fremstilling derav og rekombinant plasmid inneholdende et dna-fragment som koder for polypeptidet
IT8505195A0 (it) Nuovo gene beta-urogastrone, corrispondenti plasmidi ricombinanti, corrispondenti trasformanti e metodo per lapreparazione di questi e del beta-urogastrone.
FI841288A0 (fi) Rekombinant-dna-kod foer uttryckning av polypeptid.
DK155184A (da) Humant interferon-gamma-polypeptid og fremgangsmaade til fremstilling deraf, rekombinant plasmid omfattende et dna-fragment, som koder for peptidet, og mikroorganisme transformeret med plasmidet
DK196188D0 (da) Fremgangsmaade til fremstilling af et polypeptid, der kan kodes for genetisk, og anvendelse heraf
DK375487D0 (da) Rekombinant-pseudorabiesvirus, dets anvendelse til proteinproduktion og saaledes fremstillede produkter
EP0149241A3 (en) Dna base sequence containing regions involved in the production and secretion of a protein, recombinant dna including the whole or a part of the dna base sequence, and method of producing proteins by use of the recombinant dna
DK366589A (da) Humant protein c-mutant, dens fremstilling og dna, som koder derfor
EP0170266A3 (en) Process for producing protein, and vector, recombinant dna and transformant used therefor
NO882227D0 (no) Episomal vektor for ekspresjon av utvalgte dna-fragmenter som koder for polypeptider i pattedyrceller og fremgangsmaate til fremstilling av vektorene.
DK447083A (da) Dna, som koder for humant interferon-gamma, rekombinant-dna indeholdende denne dna, mikroorganisme indeholdende rekombinant-dna'en og fremgangsmaade til fremstilling af humant interferon-gamma-polypeptid
DK244988A (da) Fremgangsmaade til fremstilling af et polypeptid, der kan kodes for genetisk
DE68918519D1 (de) DNA, welche für ein antikoagulierendes Polypeptid kodiert.
DK712488A (da) Oploeselig, rekombinant fcepsilon-receptor og fremgangsmaade til fremstilling heraf
DK580188D0 (da) Ekskpressionsplasmid, e.coli-vaertscelle og okse-somatotropin-lignende polypeptid
ES553374A0 (es) Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes.
NO179373C (no) Rekombinant vektor istand til å uttrykke et glykoprotein, transformant som uttrykker et glykoprotein og fremgangsmåte for fremstilling av et glykoprotein

Legal Events

Date Code Title Description
MK1K Patent expired